Recombinant human erythropoietin administration in cardiac surgery
| Autor: | Neyyir Tuncay Eren, Levent Yazicioğlu, Hakkı Akalin, Mustafa Şirlak, Atilla Aral, Refik Taşöz, Mustafa Inan, Bülent Kaya, Sadık Eryilmaz |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors Anemia law.invention law Preoperative Care medicine High doses Humans Erythropoiesis Single-Blind Method Coronary Artery Bypass Erythropoietin Aged Morning Aged 80 and over business.industry Middle Aged medicine.disease Recombinant Proteins Cardiac surgery Anesthesia Recombinant DNA Female Surgery Hemoglobin Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | The Journal of Thoracic and Cardiovascular Surgery. 122:741-745 |
| ISSN: | 0022-5223 |
| DOI: | 10.1067/mtc.2001.115426 |
| Popis: | Objective: Postoperative anemia and multiple blood transfusions are still important problems in cardiac surgery. During the past few years, there have been some reports indicating that multiple recombinant human erythropoietin infusions starting at least 2 weeks before the operation induced erythropoiesis. We aimed to reduce the risk of adverse reactions of high doses of recombinant human erythropoietin and reduce the period of hospitalization by using it only once, 4 days before the operation. Methods: Twenty-five patients received recombinant human erythropoietin 4 days before the operation, and 28 patients comprised the control group. All the hematologic parameters of the patients are measured on the day of admission, the day before the operation (fourth day), the first day after the operation, and 1 week later. Results: In the recombinant human erythropoietin group the mean hemoglobin concentration increased on the morning of the operation (14.5 ± 0.52 g/dL in the recombinant human erythropoietin group and 12.4 ± 0.65 in the control group, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|